✓ Translated by DotMD AI Clinical Council Source: Future oncology (London, England) • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #33164569 ↗

Phase III Randomized Trial: The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050 (N = 448)

Original Paper Title: “The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 448
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • There were no clinically meaningful changes in functioning and overall QoL in either treatment group. Conclusion: Longer treatment duration, enabled by dose reduction, allowed patients on dacomitinib to improve treatment-related symptoms and maintain functioning and overall QoL for longer than gefitinib.
  • Study Design & Sample: Phase III Randomized Trial published in Future oncology (London, England) (N = 448 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Future oncology (London, England) (2021), this phase iii randomized trial evaluating 448 human participants investigated: Aim: Patient-reported symptoms, functioning and overall quality of life (QoL) were compared between dacomitinib and gefitinib in ARCHER 1050. Key clinical takeaway: There were no clinically meaningful changes in functioning and overall QoL in either treatment group. Conclusion: Longer treatment duration, enabled by dose reduction, allowed patients on dacomitinib to improve treatment-related symptoms and maintain functioning and overall QoL for longer than gefitinib.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Future oncology (London, England), 2021-03-15; N = 448; Rigor 87/100): There were no clinically meaningful changes in functioning and overall QoL in either treatment group. Conclusion: Longer treatment duration, enabled by dose reduction, allowed patients on dacomitinib to improve treatment-related symptoms and maintain functioning and overall QoL for longer than gefitinib.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: dacomitinib → Rx: gefitinib → Rx: quality-choice-effervescent-cold-relief-plus-aspirin-chlorpheniramine → Rx: quality-choice-pain-relief-powder-aspirin-and-caffeine → Condition: mesonephroma-benign → Condition: carcinoma-verrucous →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 33164569: Phase III Randomized Trial: The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050 (N = 448)

3 of 3 Free Questions Remaining